HDAC6 and melanoma: Combining Nexturastat (HDAC6 inhibitor) with an anti-PD-1 agent has been reported to suppress tumor growth, decrease the level of pro-tumorigenic M2 macrophages and upregulate effector T cells in melanoma (104).